Recurrent Disease Completed Phase 1 Trials for Belinostat (DB05015)

IndicationStatusPhase
DBCOND0028541 (Recurrent Disease)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00351975Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesTreatment